135 related articles for article (PubMed ID: 37713234)
1. CD39 (ENTPD1) in tumors: a potential therapeutic target and prognostic biomarker.
Li C; Zhang L; Jin Q; Jiang H; Wu C
Biomark Med; 2023 Jun; 17(12):563-576. PubMed ID: 37713234
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase inhibitor ceritinib blocks ectonucleotidase CD39 - a promising target for cancer immunotherapy.
Schäkel L; Mirza S; Winzer R; Lopez V; Idris R; Al-Hroub H; Pelletier J; Sévigny J; Tolosa E; Müller CE
J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35981785
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
4. Regulatory role of CD39 and CD73 in tumor immunity.
Kaplinsky N; Williams K; Watkins D; Adams M; Stanbery L; Nemunaitis J
Future Oncol; 2024 Apr; ():1-14. PubMed ID: 38652041
[TBL] [Abstract][Full Text] [Related]
5. IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.
Fang F; Cao W; Mu Y; Okuyama H; Li L; Qiu J; Weyand CM; Goronzy JJ
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35730568
[TBL] [Abstract][Full Text] [Related]
6. Reversal of the CD8
Li J; Huang HH; Tu B; Zhou MJ; Hu W; Fu YL; Li XY; Yang T; Song JW; Fan X; Jiao YM; Xu RN; Zhang JY; Zhou CB; Yuan JH; Zhen C; Shi M; Wang FS; Zhang C
Front Immunol; 2021; 12():687296. PubMed ID: 34177939
[TBL] [Abstract][Full Text] [Related]
7. CD39 - A bright target for cancer immunotherapy.
Guo S; Han F; Zhu W
Biomed Pharmacother; 2022 Jul; 151():113066. PubMed ID: 35550530
[TBL] [Abstract][Full Text] [Related]
8. Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.
Shevchenko I; Mathes A; Groth C; Karakhanova S; Müller V; Utikal J; Werner J; Bazhin AV; Umansky V
Oncoimmunology; 2020 Apr; 9(1):1744946. PubMed ID: 33457090
[TBL] [Abstract][Full Text] [Related]
9. Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate.
Feng L; Sun X; Csizmadia E; Han L; Bian S; Murakami T; Wang X; Robson SC; Wu Y
Neoplasia; 2011 Mar; 13(3):206-16. PubMed ID: 21390184
[TBL] [Abstract][Full Text] [Related]
10. Ectonucleotidase CD39 and Checkpoint Signalling Receptor Programmed Death 1 are Highly Elevated in Intratumoral Immune Cells in Non-small-cell Lung Cancer.
Tøndell A; Wahl SGF; Sponaas AM; Sørhaug S; Børset M; Haug M
Transl Oncol; 2020 Jan; 13(1):17-24. PubMed ID: 31733591
[TBL] [Abstract][Full Text] [Related]
11. Review immune response of targeting CD39 in cancer.
Liu Y; Li Z; Zhao X; Xiao J; Bi J; Li XY; Chen G; Lu L
Biomark Res; 2023 Jun; 11(1):63. PubMed ID: 37287049
[TBL] [Abstract][Full Text] [Related]
12. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
[TBL] [Abstract][Full Text] [Related]
13. Glioma Stem Cells Upregulate CD39 Expression to Escape Immune Response through SOX2 Modulation.
Liu B; Cao Y; Li Y; Ma H; Yang M; Zhang Q; Li G; Zhang K; Wu Y; Zhou Y; Yang W; Sun T
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159053
[TBL] [Abstract][Full Text] [Related]
14. CD39/CD73/A2AR pathway and cancer immunotherapy.
Xia C; Yin S; To KKW; Fu L
Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
[TBL] [Abstract][Full Text] [Related]
15. In lung adenocarcinoma, low expression of the cell surface extracellular nucleotidase CD39 is related to immune infiltration and a poor prognosis.
Shao L; Wang X; Yu Q; Gong J; Zhang X; Zhou Y
J Thorac Dis; 2022 Dec; 14(12):4938-4950. PubMed ID: 36647506
[TBL] [Abstract][Full Text] [Related]
16. ENTPD1/CD39 is a promising therapeutic target in oncology.
Bastid J; Cottalorda-Regairaz A; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A
Oncogene; 2013 Apr; 32(14):1743-51. PubMed ID: 22751118
[TBL] [Abstract][Full Text] [Related]
17. The ecto-ATPDase CD39 is involved in the acquisition of the immunoregulatory phenotype by M-CSF-macrophages and ovarian cancer tumor-associated macrophages: Regulatory role of IL-27.
d'Almeida SM; Kauffenstein G; Roy C; Basset L; Papargyris L; Henrion D; Catros V; Ifrah N; Descamps P; Croue A; Jeannin P; Grégoire M; Delneste Y; Tabiasco J
Oncoimmunology; 2016 Jul; 5(7):e1178025. PubMed ID: 27622030
[TBL] [Abstract][Full Text] [Related]
18. Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.
Nagate Y; Ezoe S; Fujita J; Okuzaki D; Motooka D; Ishibashi T; Ichii M; Tanimura A; Kurashige M; Morii E; Fukushima T; Suehiro Y; Yokota T; Shibayama H; Oritani K; Kanakura Y
Leukemia; 2021 Jan; 35(1):107-118. PubMed ID: 32203145
[TBL] [Abstract][Full Text] [Related]
19. Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer.
Laumont CM; Wouters MCA; Smazynski J; Gierc NS; Chavez EA; Chong LC; Thornton S; Milne K; Webb JR; Steidl C; Nelson BH
Clin Cancer Res; 2021 Jul; 27(14):4089-4100. PubMed ID: 33963000
[TBL] [Abstract][Full Text] [Related]
20. High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma.
Zhang B; Cheng B; Li FS; Ding JH; Feng YY; Zhuo GZ; Wei HF; Zhao K
Tumour Biol; 2015 Dec; 36(12):9411-9. PubMed ID: 26113408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
